MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.ajkd.2013.02.374

Медицинская библиотека · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2013

Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis.

Zhu Bin, Wang Ying, Jardine Meg, Jun Min, Lv Ji-Cheng, Cass Alan, Liyanage Thaminda, Chen Hong-Yu, Wang Yong-jun, Perkovic Vlado

СтатьяМетаанализПоддержка исследования: вне правительства СШАСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

Preparations of the herb Tripterygium wilfordii Hook F are used widely for the treatment of chronic kidney disease in China. The efficacy and safety of Tripterygium preparations still have not been fully identified.

STUDY

DESIGN

Systematic review and meta-analysis.

SETTING & POPULATION: Patients with chronic kidney disease.

SELECTION CRITERIA FOR STUDIES: Randomized controlled trials.

INTERVENTION: Tripterygium preparations (Tripterygium glycoside tablets, Tripterygium hypoglaucum Hutch tablets, and Tripterygium granules or extracts) versus placebo, standard care, or other immunosuppressive treatment.

OUTCOMES: Weighted mean difference and summary estimates of relative risk (RR) reductions with 95% CIs were calculated with a random-effects model. Outcomes analyzed included change in proteinuria, serum creatinine level, and creatinine clearance rate, as well as remission and relapse rate and drug-related adverse events.

RESULTS

We identified 75 trials that included 4,386 participants. Overall, Tripterygium therapy reduced proteinuria by protein excretion of 628 (95% CI, -736 to -521) mg/d and reduced serum creatinine level by 0.12 (95% CI, -0.17 to -0.06) mg/dL compared with controls (both P < 0.001) in a range of kidney conditions. Tripterygium preparations also increased the rate of complete remission by 56% (95% CI, 32%-85%; P < 0.001) and of complete or partial remission by 24% (95% CI, 17%-31%; P < 0.001) while reducing relapse by 58% (95% CI, 42%-69%; P < 0.001). Tripterygium preparations increased the rate of liver function test result abnormalities (RR, 4.03; 95% CI, 2.24-7.25; P < 0.001) and altered menstruation (RR, 5.29; 95% CI, 2.09-13.38; P < 0.001).

LIMITATIONS: Suboptimal study quality, significant heterogeneity in the primary outcome.

CONCLUSIONS

Tripterygium preparations may have nephroprotective effects, but high-quality trials are required to reliably determine the balance of benefits and harms.

Для цитирования: Zhu Bin, Wang Ying, Jardine Meg, Jun Min, Lv Ji-Cheng, Cass Alan, Liyanage Thaminda, Chen Hong-Yu, Wang Yong-jun, Perkovic Vlado. Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013. DOI: 10.1053/j.ajkd.2013.02.374.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.